BioSpace News Archive

TearClear has raised $22M in a Series B funding round. The investment will be used to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications.

Merger between Chondrial Therapeutics and Zafgen completed and company began operating as Larimar Therapeutics Phase 1 clinical trial of CTI-1601 for treatment of Friedreich’s ataxia restarts after delay due to COVID-19 related restrictions $80 million private placement financing completed with biotechnology-focused institutional investors Positive opinion on Orphan Drug Designation for CTI-1601 from the European Medicines Agency Committee for Orphan Medicinal Products New Board C

Verrica Pharmaceuticals Inc. (“Verrica”) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company has entered into an exclusive worldwide license agreement with Lytix Biopharma AS (“Lytix”) to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica intends to focus initially on basal cell and squamous cell carcinomas

Data readouts for AXO-Lenti-PD and AXO-AAV-GM1 remain on-track for Q4 2020 Completed 3-year manufacturing and supply agreement with Oxford BioMedica for AXO-Lenti-PD Company had $55.5 million of cash and cash equivalents as of June 30, 2020

– Conference call scheduled for 8:00 a.m. ET today –

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) is pleased to announce that it has closed the first tranche of its non-brokered private placement (the “Offering”) by issuing 716,725 units (“Units”) at a price of $1.90 per Unit for gross proceeds of $1,361,777. Each Unit consists of one common share of the Company (“Common Share”) and one half of one Common Share purchase warrant of the Company (“Warra

Bio-Techne Corporation (NASDAQ:TECH) today announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds to the SARS-CoV-2 spike receptor binding domain (RBD) and blocks the virus from binding to its host receptor, ACE-2, inhibiting viral infection . The SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Ant

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival Opdivo is the first and only treatment to demonstrate superior efficacy in patients with esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation therapy and resection Second tumor, in addition to melanoma, where Opdivo ha

In an effort to save lives globally from the deadly COVID-19 pandemic, the XPRIZE Pandemic Alliance and the New England Complex Systems Institute announced the COVID-19 CT Scan Collaborative, a new joint effort to dramatically accelerate the use of CT scans for COVID-19 diagnoses and treatment.

Partnering with BridgeBio Pharma, MyoKardia, and BridgeBio Pharma affiliate companies Navire Pharma and QED Therapeutics to develop and commercialize cutting-edge therapeutics in China and major Asian markets, LianBio extends global development of innovative science and establishes diversified portfolio that includes late stage cardiorenal and oncology assets for China and major Asian markets SHANGHAI & PRINCETON, N.J.--( BUSINESS WIRE )-- LianBi